Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report.

De Wilde, Sigrid;Graux, Carlos
(2024) Clinical Case Reports — Vol. 12, n° 7, p. e9159 [1-8] (2024)

Files

DeWildeSClinCaseRep2024.pdf
  • Open Access
  • Adobe PDF
  • 1.45 MB
Download

Details

Authors
Abstract
(en) KEY CLINICAL MESSAGE: Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T-cell lymphoma. ABSTRACT: Effective treatments for peripheral T-cell lymphoma in the relapsed and refractory (r/r) setting are limited. However, with the development and approval of innovative therapies, effective therapeutic options are becoming available for this patient population. This case report describes the treatment course of a patient with multiple r/r nodal follicular T-helper cell lymphoma of angioimmunoblastic type. Treatment with the histone deacetylase inhibitor belinostat as bridging, enabled allogeneic stem cell transplantation and resulted in a durable complete hematologic response for at least 21 months post-transplantation.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

De Wilde, S., & Graux, C. (2024). Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report. Clinical Case Reports, 12(7), e9159 [1-8]. https://doi.org/10.1002/ccr3.9159 (Original work published 2024)